瑞舒伐他汀对不稳定性心绞痛患者炎症因子及血脂水平的影响

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Rosuvastatin on inflammatory factors and short-term prognosis in patients with unstable angina pectoris (UAP).Methods From November 2018 to April 2019,80 patients with UAP treated in our hospital were selected and randomly divided into experimental group (n=40) and control group (n=40).The experimental group was given Rosuvastatin 10 mg/time,once a day,while the control group was given Atorvastatin 20 mg/time,once a day.The levels of serum lipids,levels of high sensitivity C-reactive protein (hs-CRP),interleukin-12 (IL-12)and interleukin-23 (IL-23) were measured before treatment and 4 weeks after treatment.Results Before treatment,The total cholesterol (TC),triglyceride (TG),low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C),hs-CRP,IL-12 and IL-23 levels of two groups had no significant difference (P＜0.05).Four weeks after treatment,the levels of TC,TG,LDL-C,hs-CRP,IL-12 and IL-23 in the two groups were lower than those before treatment,and the differences were statistically significant (P＜0.05).The level of HDL-C in the control group was higher than that before treatment,and the difference was statistically significant (P＜0.05).Four weeks of after treatment,the levels of TC,TG,hs-CRP and IL-12 in the experimental group were lower than those in the control group,the differences were statistically significant (P＜0.05).Conclusion Rosuvastatin has more significant effect in improving blood lipid and inflammatory factors in patients with UAP,which is worthy of clinical application.

Key words： Atorvastatin Unstable angina pectoris Inflammatory factors Blood lipid

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	REN Zhi-chao
	SONG Zhan-chun
	ZHANG Di
	ZHANG Si-yuan
	LIN Xiao

Cite this article:

REN Zhi-chao,SONG Zhan-chun,ZHANG Di, et al. Effect of Rosuvastatin on inflammatory factors and blood lipid levels in patients with unstable angina pectoris[J]. 中国当代医药, 2020, 27(1): 34-36.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I1/34

[1]	van der Vorst EP，Doring Y，Weber C.MIF and CXCL12 in cardiovascular diseases：functional differences and similarities[J].Front Immunol，2015，373（8）：1475-1478.
[2]	Khera AV，Emdin CA，Drake I，et al.Genetic risk，adherence to a healthy lifestyle，and coronary disease[J].N Engl J Med，2016，375（24）：2349-2358.
[3]	张旭，孙振学，吕豪.不同剂量阿托伐他汀对不稳定型心绞痛患者白介素-6 和高敏C-反应蛋白的影响[J].河北医药，2012，34（2）：175-176.
[4]	何钰钏.辛伐他汀联合氯吡格雷治疗不稳定型心绞痛临床疗效及对血清hs-CRP、IL-6 水平的影响[J].实用临床医药杂志，2014，18（5）：78-80.
[5]	黄瑛，林英忠，陆政德.冠心病患者血浆IL-12 和IL-27 与左室射血分数的关系[J].临床心血管病杂志，2013，29（1）：41-43.
[6]	钱前，曾昭成，王卫兵.婴幼儿喘息性疾病与巨细胞病毒感染的关系[J].山东医药，2013，43（44）：47-48.
[7]	金晓萍，张俊杰.他汀类药物对早发冠心病急性心肌梗死患者心脏及血管内皮功能改善研究[J].北华大学学报（自然科学版），2017，18（5）：630-632.
[8]	赵春勇，高筱红，金洪珍，等.不同他汀类药物联合比伐卢定对急性心梗患者PCI 术后心肌功能、血凝状态及炎症因子水平的影响[J].海南医学，2016，27（23）：3838-3840.
[9]	陈洪云，刘玲，吴猛，等.参附注射液联合阿司匹林与氯吡格雷和低分子肝素治疗急性心肌梗死的急救体会[J].中国中西医结合急救杂志，2016，23（4）：431-432.
[10]	Arnaud C，Burger F，Steffens S，et al.Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes： new evidence for direct antiinflammatory effects of statins[J].Arterioscler Thromb Vasc Biol，2005，25（6）：1231-1236.
[11]	Voleti B，Agrawal A.Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist[J].Mol Immunol，2006，43（7）：891-896.
[12]	Mayer C，Gruber HJ，Landl EM，et al.Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3-and C/EBP-dependent fashion[J].Int J Clin Pharmacol Ther，2007，45（6）：319-327.
[13]	杨生平，杨立波.瑞舒伐他汀与阿托伐他汀对早发冠心病急性心肌梗死患者心功能、血管内皮和血脂的影响[J].当代医学，2018，24（30）：34-37.
[14]	高鹏，王萍萍.瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效对比分析[J].中国医药指南，2018，16（33）：96-97.
[15]	刘瑞，刘艳芬.瑞舒伐他汀和阿托伐他汀对冠心病患者的临床疗效及对血清中IL-35、NF-κB 水平影响的比较[J].药物评价研究，2017，40（8）：1141-1144.